As Director of the Lawson Cyclotron and PET Radiochemistry Facility, I lead a self-funded, multi-faceted clinical research program by producing Positron Emitting Radiopharmaceuticals (PERs) for clinical imaging procedures and to support our clinical and pre-clinical PET imaging research programs. As a Scientist working within a hospital setting, our research program has become adept at translating PERs truly from bench to bedside. Our facility holds a Health Canada Establishment License which certifies that we are GMP compliant, and permitted to manufacture and distribute PERs throughout Southern Ontario. In addition to holding our own market authorization for [18F]FDG, we were the first site (of 2 currently) in Canada to produce Florbetapir and Flortaucapir as a contract manufacture for Avid Radiopharmaceuticals Inc. for Alzheimer’s Disease imaging with PET. In addition, we currently support a number of clinical PET imaging studies with the PERs [18]FEPPA (neuro inflammation), [18F]sodium fluoride (bone imaging), [13N]ammonia (myocardial perfusion imaging), [15O]water (perfusion imaging). We produce a larger number of PERs for preclinical use such as [11C]HED, [11C]PHNO, [11C]DTBZ, [15O]Oxygen gas, and many more. Since opening in 2010, we have demonstrated excellent competency of developing new PERs, getting them into preclinical imaging models, and ultimately translating them into clinical studies in human subjects. My research program is focused on radionuclide product